Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

University of Strasbourg, Strasburg, Alsace, France
Neuropsychopharmacology (Impact Factor: 7.83). 09/2003; 28(9):1685-93. DOI: 10.1038/sj.npp.1300209
Source: PubMed

ABSTRACT Evidence suggests that compounds that increase the synaptic availability of more than one neurotransmitter have greater efficacy in the treatment of depression than single-acting drugs. Preclinical studies indicate that duloxetine acts to inhibit serotonin (5-HT) and norepinephrine (NE) transporters. The ability of duloxetine to alter 5-HT and NE reuptake was tested in 12 healthy male subjects. Placebo, desipramine 50 mg b.i.d., and duloxetine (80 mg q.d. or 60 mg b.i.d.) were compared in a randomized, double-blind, three-period crossover study in 12 healthy male subjects. Whole-blood 5-HT, urinary excretion of NE and major metabolites, and TYR PD30 (IV tyramine pressor dose needed to increase systolic blood pressure by 30 mmHg) were measured at steady state. Vital signs were measured periodically. Duloxetine affected 5-HT reuptake, with whole-blood 5-HT depletion vs placebo (80 mg q.d.: p=0.07; 60 mg b.i.d.: p=0.02; combined regimens: p=0.01). Cardiovascular changes reflecting increased sympathetic tone were observed with both duloxetine and desipramine, and both treatments significantly decreased whole body NE turnover (p<0.01). Duloxetine and desipramine were associated with similar mean increases in fractional extraneuronal NE concentration, although these changes did not reach statistical significance. TYR PD30 increased significantly with desipramine dosing (p<0.01). In conclusion, whole-blood measurements confirm that duloxetine inhibits platelet 5-HT uptake in vivo. Urinary and cardiovascular measurements suggest that duloxetine has an effect on NE synthesis and turnover, indicative of NE reuptake inhibition. The lack of a detectable impact of duloxetine on TYR PD30 suggests that this may not be the most sensitive indirect measure of NE reuptake when assessing dual reuptake inhibitors.

Download full-text


Available from: Peter Bieck, Mar 17, 2015
  • Source
    • "Usually duloxetine is administered in the form of capsules dosage form containing 20, 30 or 60 mg of active constituent in enteric-coated pellets and the most common doses for the treatment of major depression are 40–60 mg daily. As per the literature, numerous analytical methods have been reported for the determination of duloxetine which include liquid chromatography–tandem mass spectrometric methods (LC–MS/MS) [7] [8] [9] [10] [11] [12], liquid chromatography with single-quadrupole mass spectrometric method (LC–MS) [13] [14], gas chromatographic mass spectrometric method [15], capillary electrophoresis method [16] and high performance liquid chromatographic (HPLC) methods [17] [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes a simple, rapid and sensitive liquid chromatography/tandem mass spectrometry assay for the determination of cycloserine in human plasma using carbamazepine as internal standard (IS). Analyte and the IS were extracted from the 50μL of human plasma via protein precipitation using acetonitrile. The chromatographic separation was achieved on a C(18) column by using a mixture of acetonitrile-0.5% formic acid buffer (60:40, v/v) as the mobile phase at a flow rate of 0.8mL/min. The calibration curve obtained was linear (r(2)≥0.99) over the concentration range of 50-15,000ng/mL. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 2.5min for each sample made it possible to analyze more number of samples in short time, thus increasing the productivity. The proposed method was found to be applicable to pharmacokinetic studies.
    Journal of pharmaceutical and biomedical analysis 12/2012; 76C(1):21-27. DOI:10.1016/j.jpba.2012.11.036 · 2.83 Impact Factor
  • Source
    • "Duloxetine HCl (DUL) – (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan- 1-amine hydrochloride [1] – has an empirical formula of C 18 H 19 NOS⋅HCl and a molecular weight of 333.38 g/moL (Figure 1). It is a potent inhibitor of serotonin and norepinephrine reuptake and thus it is used for major depressive disorders [2] [3] [4]. Furthermore, it provides evidence of an effect on pain in the case of urinary incontinence [5] [6] independent of its effect on depression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. The drug was found to be stable to dry heat, photodegradation, oxidation and basic condition attempted. Successful separation of the drug from the degradation products formed under acidic stress conditions was achieved on a Hypersil C-18 column (250 mm à 4.6 mm id, 5Îm particle size) using acetonitrile: 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted with orthophosphoric acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. Quantification was achieved with photodiode array detection at 229 nm over the concentration range 1â25 Îg/ml with range of recovery 99.8â101.3 % for DUL by the RP-HPLC method. Statistical analysis proved the method to be repeatable, specific, and accurate for estimation of DUL. It can be used as a stability-indicating method due to its effective separation of the drug from its degradation products.
    Scientia Pharmaceutica 01/2010; 78(4):857-68. DOI:10.3797/scipharm.1009-11
  • Source
    • "Duloxetine , at the recommended maximum dose of 60 mg daily, attenuates TYR30 slightly (Turcotte et al., 2001), in a dose-related manner which does not plateau, even at 240 mg day À1 (Vincent et al., 2004). Chalon et al. (2003) found no effect of duloxetine at a dose of 80 mg. Since the most parsimonious assumption is that a large effect on the TYR30 is required, rather than a barely detectable one, it is curious that these authors concluded, 'the lack of a detectable impact of duloxetine on TYR PD30 suggests that this may not be the most sensitive indirect measure of NE reuptake when assessing dual reuptake inhibitors.' "
    [Show abstract] [Hide abstract]
    ABSTRACT: New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful. The relative toxicity of TCAs continues to be more precisely defined, as do TCA interactions with selective serotonin reuptake inhibitors (SSRIs). TCA interactions with monoamine oxidase inhibitors (MAOIs) have been, historically, an uncertain and difficult question, but are now well understood, although this is not reflected in the literature. The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs. Clomipramine is the only available antidepressant drug that has good evidence of clinically relevant serotonin and noradrenaline reuptake inhibition (SNRI). These data assist drug selection for monotherapy and combination therapy and predict reliably how and why pharmacodynamic and pharmacokinetic interactions occur. In comparison, two newer drugs proposed to have SNRI properties, duloxetine and venlafaxine, may have insufficient NRI potency to be effective SNRIs. Combinations such as sertraline and nortriptyline may therefore offer advantages over drugs like venlafaxine that have fixed ratios of SRI/NRI effects that are not ideal. However, no TCA/SSRI combination is sufficiently safe to be universally applicable without expert knowledge. Standard texts (e.g. the British National Formulary) and treatment guidelines would benefit by taking account of these new data and understandings.
    British Journal of Pharmacology 08/2007; 151(6):737-48. DOI:10.1038/sj.bjp.0707253 · 4.99 Impact Factor